Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 8/20 | 0.56 |
| ▸ | CALCR | P30988 | 8/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.54 |
| ▸ | NPY2R | P49146 | 7/20 | 0.53 |
| ▸ | NPY4R | P50391 | 7/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.53 |
| ▸ | NPY1R | P25929 | 5/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30085017 | 0.92 | CXCR4 (0.60) | CXCR4NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29616793 | 0.89 | RAMP3 (0.49) | RAMP3CALCRCXCR4 | |
| SCHEMBL31474426 | 0.89 | RAMP3 (0.61) | RAMP3CALCRCXCR4NPY2RNPY4R | |
| SCHEMBL29375786 | 0.89 | NPY2R (0.58) | RAMP3CALCRCXCR4NPY2RNPY4R | |
| SCHEMBL31437159 | 0.89 | CXCR4 (0.54) | CXCR4NPY2RNPY4RNPY5RNPY1R | |
| Qatvgdvntdrpglldlk SCHEMBL30399126 | 0.88 | NPY2R (0.60) | RAMP3CALCRCXCR4NPY2RNPY4R | |
| SCHEMBL30974402 | 0.88 | NPY2R (0.55) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30906350 | 0.88 | NPY2R (0.59) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL29380215 | 0.88 | RAMP3 (0.53) | RAMP3CALCRCXCR4NPY2RNPY4R | |
| SCHEMBL30930178 | 0.88 | CALCR (0.53) | RAMP3CALCRCXCR4NPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230076768-A1 | IL2 Orthologs and Methods of Use | SYNTHEKINE, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230076768-A1 | IL2 Orthologs and Methods of Use | IL2RA, IL23R, IL2 | RAMP3 1517/4885CALCR 1207/4885CXCR4 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.